^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    pan-RSK inhibitor

    Related drugs:
    1m
    Dauntless-1: Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer (clinicaltrials.gov)
    P1/2, N=61, Recruiting, Phoenix Molecular Designs | Trial completion date: Mar 2026 --> Oct 2026 | Trial primary completion date: Dec 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    fulvestrant • PMD-026